Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2019

View Archived Issues

Novel rat model of multiple system atrophy unresponsive to L-dopa

Botox for -- well, against -- mosquitoes

PTEN and CF

Emmaus Life Sciences screens first patient in phase I diverticulosis study

Enanta initiates phase I study of EDP-514 for the treatment of HBV infection

Promising topline results presented from phase III program of Epsolay in papulopustular rosacea

Pediatric registrational trial of rivogenlecleucel meets primary endpoint

Skyhawk and Merck & Co. to discover and develop novel small molecules that modulate RNA splicing

Novel recombinant R2 pyocin cream for the treatment of P. aeruginosa-infected wounds

Adipokines as potential biomarkers of presence and severity of diabetic retinopathy in T2DM

[86/90Y]DTPA-ALT-836 shows potential in pancreatic cancer theranostics

Autonomic nerve manipulation affects breast cancer progression

Tyme reports phase II data for SM-88 in pancreatic cancer patients with poor prognosis

Zhengzhou University describes Helicobacter pylori-neutrophil activating proteins

Theraphage presents bacteriophage proteins fused to cancer antigens

Lundbeck discovers phosphodiesterase PDE1 inhibitors

New farnesoid X receptor agonists identified at Enanta Pharmaceuticals

Zafgen presents new methionine aminopeptidase 2 inhibitors

Targovax reports part 1 data from study of ONCOS-102 with Keytruda in melanoma

Preliminary data from phase I/II study of Onivyde in first-line pancreatic cancer

Efficacy of SPR-206 against Gram-negative bacteria in murine thigh and lung infection models

Aivita reports new data from ongoing phase II trial of cancer immunotherapy in glioblastoma

Phase III study of camrelizumab in esophageal squamous cell carcinoma meets primary endpoint

Ultra-broad-spectrum beta-lactamase inhibitor QPX-7728 shows early development potential

Primary objective met in PK/PD trial of imeglimin in patients with type 2 diabetes and CKD